2-[2-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one | 1260585-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[2-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one
• 英文别名: 2-[2-(3,3-dimethyl-2,3-dihydroindol-1-yl)-2-oxoethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one；2-[2-(3,3-dimethyl-2H-indol-1-yl)-2-oxoethyl]-4-morpholin-4-yl-1H-pyrimidin-6-one
• CAS: 1260585-05-4
• 化学式: C₂₀H₂₄N₄O₃
• 分子量: 368.436
• InChiKey: SONKMXSQGHFTFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ethyl [4-(morpholin-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]acetate 在 吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 63.0h， 生成 2-[2-(3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one
  参考文献：
  名称：

  JP5680638

  摘要：

  公开号：

文献信息

• NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS
  申请人：CARRY Jean-Christophe

  公开号：US20120270867A1

  公开（公告）日：2012-10-25

  The invention relates to the novel materials of formula (I), where: R1 is an optionally substituted aryl or heteroaryl; R is an H or, when formed with R1, a 5- or 6-member ring fused with an aryl or heretoaryl group optionally containing one or more of O, S, N, NH, and Nalk, being optionally substituted; R2 and R3 are, independently, an H, Hal, or alkyl optionally substituted by one or more Hal; R4 is H; and R5 is an H or alkyl optionally substituted by one or more halogen atoms. Said materials being in any isomeric form and the salts thereof, and are intended for drugs, particularly AKT(PKB) phosphorylation inhibitors.

  本发明涉及公式（I）的新型材料，其中：R1是可选择取代的芳基或杂环芳基；R是H或与R1形成的5-或6-成员环，与可选择含有O、S、N、NH和Nalk中的一种或多种的芳基或杂环芳基团融合，可选择取代；R2和R3分别为H、卤素或可选择取代的1个或多个卤素的烷基；R4为H；R5为H或可选择取代的1个或多个卤素原子的烷基。所述材料以任何异构形式及其盐的形式存在，用于药物，特别是AKT（PKB）磷酸化抑制剂。
• (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors
  申请人：Carry Jean-Christophe

  公开号：US08791255B2

  公开（公告）日：2014-07-29

  The invention relates to the novel materials of formula (I), wherein each of the substituents R, R1, R2, R3, R4 and R5 is as defined herein. The materials are useful as inhibitors of AKT(PKB) phosphorylation.

  本发明涉及式(I)的新型材料，其中取代基R、R1、R2、R3、R4和R5的定义如本文所述。该材料可用作AKT（PKB）磷酸化抑制剂。
• Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers
  作者：Victor Certal、Jean-Christophe Carry、Frank Halley、Angela Virone-Oddos、Fabienne Thompson、Bruno Filoche-Rommé、Youssef El-Ahmad、Andreas Karlsson、Véronique Charrier、Cécile Delorme、Alexey Rak、Pierre-Yves Abecassis、Céline Amara、Loïc Vincent、Hélène Bonnevaux、Jean-Paul Nicolas、Magali Mathieu、Thomas Bertrand、Jean-Pierre Marquette、Nadine Michot、Tsiala Benard、Marc-Antoine Perrin、Olivier Lemaitre、Stephane Guerif、Sébastien Perron、Sylvie Monget、Florence Gruss-Leleu、Gilles Doerflinger、Houlfa Guizani、Maurice Brollo、Laurence Delbarre、Luc Bertin、Patrick Richepin、Véronique Loyau、Carlos Garcia-Echeverria、Christoph Lengauer、Laurent Schio

  DOI：10.1021/jm401642q

  日期：2014.2.13

  Compelling molecular biology publications have reported the implication of phosphoinositide kinase PI3K beta in PTEN-deficient cell line growth and proliferation. These findings supported a scientific rationale for the development of PI3K beta-specific inhibitors for the treatment of PTEN-deficient cancers. This paper describes the discovery of 2-[2-(2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one (7) and the optimization of this new series of active and selective pyrimidone indoline amide PI3K beta inhibitors. 2-[2-(2-Methyl-2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one (28), identified following a carefully designed methyl scan, displayed improved physicochemical and in vitro pharmacokinetic properties. Structural biology efforts enabled the acquisition of the first X-ray cocrystal structure of p110 beta with the selective inhibitor compound 28 bound to the ATP site. The nonplanar binding mode described herein is consistent with observed structure-activity relationship for the series. Compound 28 demonstrated significant in vivo activity in a UACC-62 xenograft model in mice, warranting further preclinical investigation. Following successful development, compound 28 entered phase I/Ib clinical trial in patients with advanced cancer.
• NOUVEAUX DERIVES DE (6-OXO-1,6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE COMME INHIBITEURS DE PHOSPHORYLATION D'AKT
  申请人：SANOFI

  公开号：EP2448927B1

  公开（公告）日：2014-03-12
• NOUVEAUX DERIVES DE (6-OXO-1,6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE COMME INHIBITEURS DE PHOSPHORYLATION D'AKT(PKB)
  申请人：SANOFI

  公开号：EP2448927A1

  公开（公告）日：2012-05-09